Evidence map›Paper›PMID 30374743›Full record

ArticleEJNMMI research2018

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.

Katharina Lückerath, Liu Wei, Wolfgang P Fendler, Susan Evans-Axelsson, Andreea D Stuparu, Roger Slavik, Christine E Mona, Jeremie Calais, Matthew Rettig, Robert E Reiter and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. A Preliminary Evaluation ofPharmaceutics · 2026
    Article
  5. Article
  6. Article
  7. Comparison of mCRPC [European journal of nuclear medicine and molecular imaging · 2026
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer.European journal of nuclear medicine and molecular imaging · 2025
    Review
  14. JHU-2545 preferentially shields salivary glands and kidneys during PSMA-targeted imaging.European journal of nuclear medicine and molecular imaging · 2025
    Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Katharina LückerathDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. klueckerath@mednet.ucla.edu.ORCID http://orcid.org/0000-0001-6109-2066
Liu WeiDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Wolfgang P FendlerDepartment of Nuclear Medicine, Universitätsklinikum Essen, Essen, Germany.
Susan Evans-AxelssonLund University, Lund, Sweden.
Andreea D StuparuDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Roger SlavikDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Christine E MonaDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Jeremie CalaisDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Matthew RettigDepartment of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Robert E ReiterDepartment of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Ken HerrmannDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Caius G RaduDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Johannes CzerninDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Matthias EiberDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
University of California, Los Angeles · USEssen University Hospital · DELund University · SETUM Klinikum · DE

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
Deutsche Forschungsgemeinschaft 807122Deutsche Forschungsgemeinschaft 807454Deutsche Forschungsgemeinschaft DFG Sonderforschungsbereich 824, Project B11Fondation ARC pour la Recherche sur le Cancer SAE20160604150NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA092131NCI NIH HHS P50 CA211015Prostate Cancer Foundation 17CHAL02US Department of Energy, Office of Science Award DE-SC0012353
6 · The paper itself

Abstract

backgroundProstate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a promising yet not curative approach in castration-resistant (CR) prostate cancer (PC). Rational combination therapies may improve treatment efficacy. Here, we explored the effect of androgen receptor blockade (ARB) on PSMA expression visualized by PET and its potential additive effect when combined with

methodsMice bearing human CRPC (C4-2 cells) xenografts were treated with 10 mg/kg enzalutamide (ENZ), with 50 mg/kg bicalutamide (BIC), or vehicle (control) for 21 days. PSMA expression was evaluated by

resultsTumor growth was delayed by ARB while

conclusionARB-mediated increases in PSMA expression in PC xenografts were evident by

Indexed as

68Ga-PSMA PET/CTAndrogen receptor blockadeProstate cancerPSMARadioligand therapy

Identifiers

PMID30374743
PMCPMC6206308
OpenAlexW2898623933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.